by 
Autologous stem cell and non-stem cell based therapies have emerged as promising treatment options for various chronic medical conditions. These therapies utilize autologous stem cells and non-stem cell based products that are extracted from patient’s own body to repair and regenerate damaged tissues. Autologous therapies help treat chronic diseases like musculoskeletal disorders, cardiovascular disease and neurodegenerative conditions with minimal side effects.
The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market is estimated to be valued at US$ 98.8 Bn in 2024 and is expected to exhibit a CAGR of 4.3% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the Autologous Stem Cell and Non-Stem Cell Based Therapies are Caladrius Biosciences, Vericel Corporation, Fibrocell Science, Inc., Genzyme Corporation, BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon Corporation. These players are focusing on developing innovative therapeutic solutions and engaging in partnerships and acquisitions to strengthen their market presence.
The growing prevalence of chronic and degenerative conditions worldwide is a major factor driving the demand for autologous therapies. These therapies provide effective treatment options for chronic diseases like musculoskeletal disorders and cardiovascular diseases that have limited therapeutic alternatives. Moreover, the rising geriatric population prone to age-related health issues also contributes to market growth.
Globally, North America dominates the autologous therapies market due to rising research and development activities. However, Asia Pacific is expected to witness highest growth owing to increasing healthcare investments, rising medical tourism and growing modernization of healthcare infrastructure in emerging countries. Many players are expanding their presence in Asia to tap the growth opportunities in the region.
Market Key Trends
One of the key trends gaining traction in the autologous therapies market is the growing research in cell therapies for rare diseases. Rare diseases pose significant treatment challenges due to lack of effective therapies. Cell therapies provide new hope for patients suffering from rare genetic conditions. Companies are conducting clinical trials to evaluate the potential of autologous cell therapies in treating rare diseases like cerebral adrenoleukodystrophy (CALD) and hypoplastic left heart syndrome (HLHS). This is expected to expand therapeutic applications of autologous therapies.
Porter’s Analysis
Threat of new entrants: Low barriers to enter market with the emergence of startups with novel technologies.
Bargaining power of buyers: Large pool of buyers has relatively high bargaining power as they can negotiate on price.
Bargaining power of suppliers: A few large players exercise strong influence on pricing of raw materials and reagents.
Threat of new substitutes: Technologies such as gene therapy and cell engineering provide substitutes but have limitations currently.
Competitive rivalry: Intense competition among existing players to capture market share through innovation and strategic collaboration.
The North American region currently dominates the global market, accounting for the largest share in terms of value. This is attributed to factors such as supportive regulatory policies, high healthcare expenditure, and presence of major market players in the region.
The Asia Pacific region is poised to be the fastest growing market during the forecast period. This is attributed to factors such as rising incidence of chronic diseases, improving healthcare infrastructure, increasing disposable incomes, and growth in medical tourism in the region.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
